查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1392003

Calcineurin酶抑制剂市场：按药物类型、按给药途径、按适应症（预防器官移植排斥、自体免疫疾病、眼科疾病）、配销通路、按最终用户、按地区

Calcineurin Inhibitor Market, By Drug Type, By Route of Administration, By Indication (Organ Transplant Rejection Prevention, Autoimmune Diseases, Ophthalmic Diseases, By Distribution Channel, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2023年全球Calcineurin酶抑制剂市场规模为100.7亿美元，2030年将达206.4亿美元，2023-2030年预测期间复合年增长率为10.8%。

报告范围 报告详情
基准年 2022年 2023年市场规模 100.7亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 10.80% 2030年市场规模预测 206.4亿美元
图 1. 2023 年Calcineurin抑制剂的全球市场占有率(%)（按地区）
钙调神经磷酸酶抑制剂市场-IMG1

Calcineurin抑制剂是一种免疫抑制剂。这些药物透过抑制免疫系统活动发挥作用，从而防止免疫系统攻击移植器官。它常用于器官移植，特别是肾臟、心臟和肝臟移植。Calcineurin酶抑制剂主要有两种类型：环孢素和他克莫司。所有这些药物都已被证明可以有效预防器官排斥，但它们也可能产生严重的副作用，包括肾损伤、高血压以及感染疾病和癌症风险增加。由于器官移植和自体免疫疾病的盛行率增加，预计Calcineurin酶抑制剂的全球市场将会成长。该市场也受到新药开拓和现有药物适应症扩大的推动。然而，这些药物的副作用和移植的高成本可能会阻碍市场成长。全球Calcineurin抑制剂市场的主要企业包括诺华公司、安斯泰来製药公司、艾尔建公司和辉瑞公司。这些公司专注于开发新型和改进的Calcineurin抑制剂的研发活动。按地区划分，北美在Calcineurin抑制剂市场中占有最大份额，其次是欧洲。这是由于这些地区器官移植和自体免疫疾病的高发生率。由于该地区医疗支出的增加和器官移植意识的增强，预计亚太市场将显着增长。

市场动态：

自体自体免疫疾病和器官移植病例的增加预计将在不久的将来推动全球Calcineurin酶抑制剂市场的成长。一个主要驱动因素是对Calcineurin抑制剂的需求不断增加，以防止移植器官的排斥。他克莫司是一种Calcineurin抑制剂，是一种用于治疗器官移植患者的免疫抑制剂，可降低人体排斥移植器官的能力。

然而，与Calcineurin抑制剂相关的副作用，例如皮肤刺激和胃肠道疾病，可能会阻碍市场成长。此外，与给药药物给药相关的风险（例如肾毒性和肝毒性）预计也将在不久的将来阻碍市场成长。

本研究的主要特点

  • 本报告对全球Calcineurin酶抑制剂市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球Calcineurin抑制剂市场的主要企业。
  • 该报告的见解将使行销人员和经营团队负责人就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
  • 全球Calcineurin酶抑制剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球Calcineurin酶抑制剂市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与假设

  • 研究目标
  • 假设
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章全球Calcineurin酶抑制剂市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球Calcineurin酶抑制剂市场，依药物类型，2018-2030

  • 介绍
  • 环孢素
  • 他克莫司
  • 吡美莫司
  • 沃罗孢素
  • 其他的

第六章全球Calcineurin抑制剂市场，依给药途径，2018-2030

  • 介绍
  • 口服
  • 局部的
  • 静脉

第七章 全球Calcineurin酶抑制剂市场，依适应症划分，2018-2030 年

  • 介绍
  • 器官移植排斥反应的预防
  • 自体免疫疾病
  • 眼科疾病
  • 其他皮肤病

第8章全球Calcineurin酶抑制剂市场，依配销通路，2018-2030

  • 介绍
  • 医院药房
  • 零售药房
  • 线上药房

第 9 章全球Calcineurin酶抑制剂市场，按最终用户划分，2018-2030 年

  • 介绍
  • 医院
  • 专科诊所
  • 皮肤科中心
  • 移植中心

第10章全球Calcineurin酶抑制剂市场，按地区，2018-2030

  • 介绍
  • 北美洲
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第十一章竞争形势

  • Novartis AG
  • Amgen
  • F.Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Incyte Corporation
  • Chiesi Farmaceutici SpA
  • Astellas Pharma Inc.
  • Sanofi SA
  • Bristol Myers Squibb Company
  • Mylan NV
  • Reddy's Laboratories Ltd.
  • Senju Pharmaceutical Co. Ltd
  • Abbott
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.

第12章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5848

Global calcineurin inhibitor market size is expected to be valued at US$ 10.07 Bn in 2023, and is expected to reach US$ 20.64 Bn by 2030, exhibiting a CAGR of 10.8% during the forecast period of 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 10.07 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 10.80% 2030 Value Projection: US$ 20.64 Bn
Figure 1. Global Calcineurin Inhibitor Market Share (%), By Region, 2023
Calcineurin Inhibitor Market - IMG1

Calcineurin inhibitors are a type of immunosuppressant. These drugs work by suppressing the activity of the immune system to prevent it from attacking the transplanted organ. They are commonly used in organ transplantation, especially kidney, heart, and liver transplants. There are two main types of calcineurin inhibitors: cyclosporine and tacrolimus. Both of these drugs have been proven to be effective in preventing organ rejection, but they can also have serious side effects, including kidney damage, high blood pressure, and an increased risk of infections and cancer. The global calcineurin inhibitors market is expected to grow due to the increasing prevalence of organ transplantation and autoimmune diseases. The market is also driven by the development of new drugs and the expansion of indications for existing drugs. However, the market growth may be hindered by the side effects of these drugs and the high cost of transplantation. Key players in the global calcineurin inhibitors market include Novartis AG, Astellas Pharma Inc., Allergan, Inc., and Pfizer Inc. These companies are focusing on research and development activities to develop new and improved calcineurin inhibitors. In terms of geography, North America holds the largest share of the calcineurin inhibitors market, followed by Europe. This is due to the high prevalence of organ transplantation and autoimmune diseases in these regions. The market in Asia Pacific is expected to grow at a significant rate due to the increasing healthcare expenditure and the growing awareness about organ transplantation in this region.

Market Dynamics:

Increasing cases of autoimmune diseases and organ transplantation is expected to drive growth of the global calcineurin inhibitor market in the near future. Increasing demand for the calcineurin inhibitors to prevent rejection of transplanted organs is the major driving factor. For instance, in December 2020, Biocon, an innovation-led global biopharmaceutical company, announced the launch of Tacrolimus capsules in the U.S. Tacrolimus is a calcineurin inhibitor, an immunosuppressant used in the treatment of organ transplant patients that reduces the body's ability to reject a transplanted organ.

However, side effects associated with calcineurin inhibitors such as skin irritation and gastrointestinal disturbances may hamper the market growth. Moreover, risks connected with overdosing of the orally administered drugs such as nephrotoxicity and hepatotoxicity are also expected to hamper the market growth in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global calcineurin inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global calcineurin inhibitor market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy's Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global calcineurin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcineurin inhibitor market

Detailed Segmentation:

  • Global Calcineurin Inhibitor Market, By Drug Type:
    • Cyclosporine
    • Tacrolimus
    • Pimecrolimus
    • Voclosporin
    • Others
  • Global Calcineurin Inhibitor Market, By Route of Administration:
    • Oral
    • Topical
    • Intravenous
  • Global Calcineurin Inhibitor Market, By Indication:
    • Organ Transplant Rejection Prevention
    • Autoimmune Diseases
    • Ophthalmic Diseases
    • Other Dermatological Conditions
  • Global Calcineurin Inhibitor Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Calcineurin Inhibitor Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Dermatology Centers
    • Transplant Centers
  • Global Calcineurin Inhibitor Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Novartis AG
    • Amgen
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Incyte Corporation
    • Chiesi Farmaceutici S.p.A.
    • Astellas Pharma Inc.
    • Sanofi SA
    • Bristol Myers Squibb Company
    • Mylan N.V.
    • Dr. Reddy's Laboratories Ltd.
    • Senju Pharmaceutical Co. Ltd
    • Abbott
    • Lupin Limited
    • Vibcare Pharma Pvt. Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Calcineurin Inhibitor, By Drug Type
    • Market Calcineurin Inhibitor, By Route of Administration
    • Market Calcineurin Inhibitor, By Indication
    • Market Calcineurin Inhibitor, By Distribution Channel
    • Market Calcineurin Inhibitor, By End User
    • Market Calcineurin Inhibitor, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Calcineurin Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Calcineurin Inhibitor Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2023 - 2030
    • Segment Trends
  • Cyclosporine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Tacrolimus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Pimecrolimus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Voclosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Calcineurin Inhibitor Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Calcineurin Inhibitor Market, By Indication, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Organ Transplant Rejection Prevention
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Autoimmune Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Ophthalmic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Other Dermatological Conditions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Calcineurin Inhibitor Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Calcineurin Inhibitor Market, By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Dermatology Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Transplant Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

10. Global Calcineurin Inhibitor Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 - 2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

11. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen
  • F.Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Incyte Corporation
  • Chiesi Farmaceutici S.p.A.
  • Astellas Pharma Inc.
  • Sanofi SA
  • Bristol Myers Squibb Company
  • Mylan N.V.
  • Reddy's Laboratories Ltd.
  • Senju Pharmaceutical Co. Ltd
  • Abbott
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.
  • Analyst Views

12. Section

  • Research Methodology
  • About us